Literature DB >> 14694127

Persistent infection with ebola virus under conditions of partial immunity.

Manisha Gupta1, Siddhartha Mahanty, Patricia Greer, Jonathan S Towner, Wun-Ju Shieh, Sherif R Zaki, Rafi Ahmed, Pierre E Rollin.   

Abstract

Ebola hemorrhagic fever in humans is associated with high mortality; however, some infected hosts clear the virus and recover. The mechanisms by which this occurs and the correlates of protective immunity are not well defined. Using a mouse model, we determined the role of the immune system in clearance of and protection against Ebola virus. All CD8 T-cell-deficient mice succumbed to subcutaneous infection and had high viral antigen titers in tissues, whereas mice deficient in B cells or CD4 T cells cleared infection and survived, suggesting that CD8 T cells, independent of CD4 T cells and antibodies, are critical to protection against subcutaneous Ebola virus infection. B-cell-deficient mice that survived the primary subcutaneous infection (vaccinated mice) transiently depleted or not depleted of CD4 T cells also survived lethal intraperitoneal rechallenge for >/==" BORDER="0">25 days. However, all vaccinated B-cell-deficient mice depleted of CD8 T cells had high viral antigen titers in tissues following intraperitoneal rechallenge and died within 6 days, suggesting that memory CD8 T cells by themselves can protect mice from early death. Surprisingly, vaccinated B-cell-deficient mice, after initially clearing the infection, were found to have viral antigens in tissues later (day 120 to 150 post-intraperitoneal infection). Furthermore, following intraperitoneal rechallenge, vaccinated B-cell-deficient mice that were transiently depleted of CD4 T cells had high levels of viral antigen in tissues earlier (days 50 to 70) than vaccinated undepleted mice. This demonstrates that under certain immunodeficiency conditions, Ebola virus can persist and that loss of primed CD4 T cells accelerates the course of persistent infections. These data show that CD8 T cells play an important role in protection against acute disease, while both CD4 T cells and antibodies are required for long-term protection, and they provide evidence of persistent infection by Ebola virus suggesting that under certain conditions of immunodeficiency a host can harbor virus for prolonged periods, potentially acting as a reservoir.

Entities:  

Mesh:

Year:  2004        PMID: 14694127      PMCID: PMC368745          DOI: 10.1128/jvi.78.2.958-967.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Re-emergence of ebola haemorrhagic fever in Gabon.

Authors:  E M Leroy; S Souquière; P Rouquet; D Drevet
Journal:  Lancet       Date:  2002-02-23       Impact factor: 79.321

2.  An outbreak of Ebola in Uganda.

Authors:  S I Okware; F G Omaswa; S Zaramba; A Opio; J J Lutwama; J Kamugisha; E B Rwaguma; P Kagwa; M Lamunu
Journal:  Trop Med Int Health       Date:  2002-12       Impact factor: 2.622

3.  Update: filovirus infections among persons with occupational exposure to nonhuman primates.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1990-04-27       Impact factor: 17.586

4.  The increasing burden of infectious diseases on hospital services at St Mary's Hospital Lacor, Gulu, Uganda.

Authors:  S Accorsi; M Fabiani; M Lukwiya; P A Onek; P D Mattei; S Declich
Journal:  Am J Trop Med Hyg       Date:  2001 Mar-Apr       Impact factor: 2.345

5.  A case of Ebola virus infection.

Authors:  R T Emond; B Evans; E T Bowen; G Lloyd
Journal:  Br Med J       Date:  1977-08-27

6.  Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily.

Authors:  Lisa E Hensley; Howard A Young; Peter B Jahrling; Thomas W Geisbert
Journal:  Immunol Lett       Date:  2002-03-01       Impact factor: 3.685

7.  Sequence analysis of the GP, NP, VP40 and VP24 genes of Ebola virus isolated from deceased, surviving and asymptomatically infected individuals during the 1996 outbreak in Gabon: comparative studies and phylogenetic characterization.

Authors:  Eric M Leroy; Sylvain Baize; Elie Mavoungou; Cristian Apetrei
Journal:  J Gen Virol       Date:  2002-01       Impact factor: 3.891

8.  Enzyme immunosorbent assay for Ebola virus antigens in tissues of infected primates.

Authors:  T G Ksiazek; P E Rollin; P B Jahrling; E Johnson; D W Dalgard; C J Peters
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

9.  Mechanisms of monoclonal antibody-mediated protection against virulent Semliki Forest virus.

Authors:  W A Boere; B J Benaissa-Trouw; T Harmsen; T Erich; C A Kraaijeveld; H Snippe
Journal:  J Virol       Date:  1985-05       Impact factor: 5.103

10.  T cell memory. Long-term persistence of virus-specific cytotoxic T cells.

Authors:  B D Jamieson; R Ahmed
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

View more
  27 in total

1.  Functional genomics reveals the induction of inflammatory response and metalloproteinase gene expression during lethal Ebola virus infection.

Authors:  Cristian Cilloniz; Hideki Ebihara; Chester Ni; Gabriele Neumann; Marcus J Korth; Sara M Kelly; Yoshihiro Kawaoka; Heinz Feldmann; Michael G Katze
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

2.  CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates.

Authors:  Nancy J Sullivan; Lisa Hensley; Clement Asiedu; Thomas W Geisbert; Daphne Stanley; Joshua Johnson; Anna Honko; Gene Olinger; Michael Bailey; Joan B Geisbert; Keith A Reimann; Saran Bao; Srinivas Rao; Mario Roederer; Peter B Jahrling; Richard A Koup; Gary J Nabel
Journal:  Nat Med       Date:  2011-08-21       Impact factor: 53.440

Review 3.  Progress in filovirus vaccine development: evaluating the potential for clinical use.

Authors:  Darryl Falzarano; Thomas W Geisbert; Heinz Feldmann
Journal:  Expert Rev Vaccines       Date:  2011-01       Impact factor: 5.217

Review 4.  Ebola haemorrhagic fever.

Authors:  Heinz Feldmann; Thomas W Geisbert
Journal:  Lancet       Date:  2011-03-05       Impact factor: 79.321

5.  Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway.

Authors:  James E Strong; Gary Wong; Shane E Jones; Allen Grolla; Steven Theriault; Gary P Kobinger; Heinz Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-03       Impact factor: 11.205

Review 6.  Immune barriers of Ebola virus infection.

Authors:  Anita K McElroy; Elke Mühlberger; César Muñoz-Fontela
Journal:  Curr Opin Virol       Date:  2018-02-16       Impact factor: 7.090

7.  Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus.

Authors:  Amy L Hartman; Brian H Bird; Jonathan S Towner; Zoi-Anna Antoniadou; Sherif R Zaki; Stuart T Nichol
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

Review 8.  Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it.

Authors:  Jeffrey E Lee; Erica Ollmann Saphire
Journal:  Curr Opin Struct Biol       Date:  2009-06-24       Impact factor: 6.809

Review 9.  Mouse models for filovirus infections.

Authors:  Steven B Bradfute; Kelly L Warfield; Mike Bray
Journal:  Viruses       Date:  2012-09-07       Impact factor: 5.048

Review 10.  Use of the Syrian hamster as a new model of ebola virus disease and other viral hemorrhagic fevers.

Authors:  Victoria Wahl-Jensen; Laura Bollinger; David Safronetz; Fabian de Kok-Mercado; Dana P Scott; Hideki Ebihara
Journal:  Viruses       Date:  2012-12-14       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.